Affymax Appoints Daniel K. Spiegelman to Board of Directors
October 06 2006 - 9:00AM
PR Newswire (US)
PALO ALTO, Calif., Oct. 6 /PRNewswire/ -- Affymax, Inc. a
clinical-stage pharmaceutical company, today announced the
appointment of Daniel K. Spiegelman to the Company's board of
directors. Mr. Spiegelman is currently senior vice president and
chief financial officer (CFO) of CV Therapeutics (NASDAQ:CVTX), a
position he has held since 1999. "Dan Spiegelman has an extensive
background in the financial and commercial issues facing growing
biotechnology companies, and he is an important addition to
Affymax's board. He has helped CV Therapeutics raise more than $1
billion in financing and has overseen its transition from an
R&D-focused company into a commercial entity with two approved
products and approximately 700 employees," said Arlene M. Morris,
president and chief executive officer of Affymax. "His experience
will be valuable to Affymax as we advance our lead product
candidate Hematide(TM) through clinical development and, if
successful, into commercialization for the treatment of anemia in
patients with chronic kidney disease and cancer." Mr. Spiegelman
joined CV Therapeutics in January 1998 as vice president and CFO. A
publicly traded biopharmaceutical company, CV Therapeutics is
focused on applying molecular cardiology to the discovery,
development, and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. Previously, he was
employed by Genentech, Inc., where he held a number of positions in
the treasury department, including treasurer. Mr. Spiegelman also
serves as a member of the board of directors of Cyclacel
Pharmaceuticals, Inc. He previously served as a director for Xcyte
Therapies, Inc. before its merger with Cyclacel in March 2006. He
holds a B.A. in economics from Stanford University and an M.B.A.
from Stanford Graduate School of Business. About Affymax, Inc.
Affymax, Inc. is a clinical-stage biopharmaceutical company
developing novel peptide-based drugs to improve the treatment of
serious and often life-threatening conditions. Affymax's lead
product candidate, Hematide(TM), is currently in Phase 2 clinical
trials for the treatment of anemia associated with chronic kidney
disease and cancer. DATASOURCE: Affymax, Inc. CONTACT: Corporate,
Mary Fermi, Senior Director, Commercial Development, of Affymax,
Inc., +1-650-812-8722; or Media, Jani Bergan of WeissComm Partners,
+1-415-946-1064, or , for Affymax, Inc. Web site:
http://www.affymax.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024